IP Library Granted Patent US 10,435,616
Granted Patent B2
US 10,435,616 · App. 15/522,906 · Granted Oct 8, 2019

Cationic ammonium surfactants as low dosage hydrate inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,435,616
App. No.
15/522,906
Granted
Oct 8, 2019
Kind
B2
Abstract

This disclosure relates to anti-agglomerant low dosage hydrate inhibitors that can inhibit the formation of hydrate agglomerants and/or plugs. The anti-agglomerant low dosage hydrate inhibitors can be surfactants. The hydrate inhibitors can be used for inhibiting, retarding, mitigating, reducing, controlling and/or delaying formation of hydrocarbon hydrates, agglomerants of hydrates, and/or plugs. The hydrate inhibitors can be applied to prevent, reduce, and/or mitigate plugging of conduits, pipes, transfer lines, valves, and other places or equipment where hydrocarbon hydrate solids can form. The hydrate inhibitors can be zwitterionic or cationic ammonium surfactants.

Claims (23)

1. A hydrate inhibitor composition comprising a hydrate-inhibiting effective amount of a compound of Formula (I), or an acid, a free base, a zwitterion, or a salt thereof:

wherein

R 1 is hydrogen, a C 1 to C 20 substituted or unsubstituted alkyl group, or a C 1 to C 20 substituted or unsubstituted alkenyl group;

R 2 is an alkylcarboxyl, or an alkylamido group;

R 4 is hydrogen, a C 1 to C 20 substituted or unsubstituted alkyl group, or a C 1 to C 20 substituted or unsubstituted alkenyl group;

R 5 is C 10 to C 20 alkyl or —R 50 —NR 6 R 7 , wherein R 50 is C 1 to C 5 alkylene, and R 6 and R 7 are independently C 1 to C 6 alkyl; and

R 8 is a C 2 to C 10 substituted or unsubstituted alkylene group.

2. The composition of claim 1 , wherein the substituted alkyl group of R 1 and R 4 has at least one of the —CH 2 — groups in the chain replaced with an ether, an amine, an amide, a carbonyl, or an ester functional group or at least one of the hydrogen atoms attached to a carbon atom of the chain is replaced with a hydroxy, a halo, or an amine group.

3. The composition of claim 2 , wherein the substituted alkyl group of R 1 and R 4 has at least one of the —CH 2 — groups in the chain replaced with an amine.

4. The composition of claim 1 , wherein R 8 is —C 2 H 4 —.

5. The composition of claim 4 , wherein R 1 is C 10 to C 20 alkyl or —R 10 —NR 6 R 7 , wherein R 10 is C 1 to C 5 alkylene, and R 6 and R 7 are independently substituted or unsubstituted C 1 to C 6 alkyl.

6. The composition of claim 1 , wherein R 2 is —R 20 —C(O)O − , wherein R 20 is C 1 to C 4 alkylene.

7. The composition of claim 1 , wherein R 4 is hydrogen.

8. The composition of claim 6 , wherein R 20 is C 2 H 4 , and R 50 is C 3 H 6 .

9. The composition of claim 1 , wherein when the compound is in its salt form, the counterion is selected from the group consisting of a halide, a carboxylate, hydrogen sulfate, dihydrogen phosphate, nitrate, and a combination thereof.

10. The composition of claim 9 , wherein the counterion is an acetate, an acrylate, or a combination thereof.

11. The composition of claim 1 , wherein the composition further comprises a thermodynamic hydrate inhibitor, a kinetic hydrate inhibitor, an anti-agglomerant, or a combination thereof.

12. The composition of claim 1 , wherein the composition further comprises a polar solvent, a nonpolar solvent, or a mixture thereof.

13. A method of inhibiting formation of hydrate agglomerants in a fluid comprising water, a gas, and optionally a liquid hydrocarbon, comprising contacting the fluid with an effective amount of a hydrate inhibitor composition of claim 1 .

14. The method of claim 13 , wherein the effective amount is from about 0.1 to about 10 volume %, based on an amount of water.

15. A hydrate inhibitor composition comprising a hydrate-inhibiting effective amount of:

wherein R 11 is C 8 to C 20 alkyl, and R 12 and R 13 are independently C 1 to C 6 alkyl.

16. The composition of claim 15 wherein the compound of Formula 1 is:

Assignments (6)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jul 17, 2025
From: JPMORGAN CHASE BANK, N.A.
To: CHAMPIONX LLC; APERGY ESP SYSTEMS, LLC; APERGY BMCS ACQUISITION CORP; HARBISON-FISCHER, INC.; NORRIS RODS, INC.,; NORRIS RODS, INC.,; NORRISEAL-WELLMARK, INC.; PCS FERGUSON, INC.; QUARTZDYNE, INC.; US SYNTHETIC CORPORATION
Reel/Frame 072004/0019 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2022
From: BANK OF AMERICA, N.A.
To: CHAMPIONX USA INC.
Reel/Frame 060304/0267 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2020
From: ECOLAB USA INC.
To: CHAMPIONX USA INC.
Reel/Frame 053849/0537 →
SECURITY INTEREST Recorded Jun 5, 2020
From: CHAMPIONX USA INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 052848/0368 →
SECURITY INTEREST Recorded Jun 5, 2020
From: CHAMPIONX USA INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 053250/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2017
From: LUCENTE-SCHULTZ, REBECCA MICHELE; SERVESKO, JEFF
To: ECOLAB USA INC.
Reel/Frame 042318/0599 →